CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 139 filers reported holding CRINETICS PHARMACEUTICALS IN in Q2 2023. The put-call ratio across all filers is 19.18 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,955,041 | +129.3% | 435,610 | +38.9% | 0.03% | +65.0% |
| Q2 2023 | $5,651,036 | -18.9% | 313,598 | -27.7% | 0.02% | -80.8% |
| Q1 2023 | $6,965,142 | -6.2% | 433,695 | +6.9% | 0.10% | -23.0% |
| Q4 2022 | $7,421,730 | +51.2% | 405,559 | +62.2% | 0.14% | +43.6% |
| Q3 2022 | $4,910,000 | +70.8% | 250,014 | +62.2% | 0.09% | +19.0% |
| Q2 2022 | $2,874,000 | -28.7% | 154,092 | -16.0% | 0.08% | -26.9% |
| Q1 2022 | $4,029,000 | +61.9% | 183,543 | +109.5% | 0.11% | +40.3% |
| Q4 2021 | $2,489,000 | +1355.6% | 87,608 | +624.0% | 0.08% | +600.0% |
| Q4 2020 | $171,000 | – | 12,100 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 3,375,169 | $76,819,000 | 7.66% |
| RA Capital Management | 1,875,209 | $42,680,000 | 1.84% |
| Perceptive Advisors | 2,587,953 | $58,901,000 | 1.66% |
| EMORY UNIVERSITY | 97,035 | $2,209,000 | 1.55% |
| New Leaf Venture Partners, L.L.C. | 167,700 | $3,817,000 | 1.05% |
| Orbimed Advisors | 1,914,282 | $43,569,000 | 0.67% |
| Opaleye Management Inc. | 73,000 | $1,661,000 | 0.46% |
| Novo Holdings A/S | 135,009 | $3,073,000 | 0.46% |
| Virtus ETF Advisers LLC | 7,934 | $181,000 | 0.38% |
| Eventide Asset Management | 384,000 | $8,740,000 | 0.30% |